Vital Therapies Inc (NASDAQ:VTL) shares gapped up before the market opened on Tuesday . The stock had previously closed at $0.24, but opened at $0.25. Vital Therapies shares last traded at $0.43, with a volume of 50099852 shares trading hands.

VTL has been the topic of a number of analyst reports. BTIG Research reaffirmed a “hold” rating on shares of Vital Therapies in a research note on Monday, May 28th. ValuEngine raised Vital Therapies from a “hold” rating to a “buy” rating in a research note on Friday, June 29th. BidaskClub raised Vital Therapies from a “hold” rating to a “buy” rating in a research note on Saturday, June 30th. William Blair raised Vital Therapies from a “market perform” rating to an “outperform” rating in a research note on Monday, August 6th. Finally, Cantor Fitzgerald initiated coverage on Vital Therapies in a research note on Monday, August 20th. They set an “overweight” rating and a $18.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, Vital Therapies currently has an average rating of “Hold” and an average target price of $12.00.

The company has a market cap of $14.83 million, a P/E ratio of -0.23 and a beta of 4.16.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. equities research analysts expect that Vital Therapies Inc will post -1.12 EPS for the current year.

In related news, Director Muneer A. Satter sold 11,382,277 shares of the stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $0.36, for a total value of $4,097,619.72. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Muneer A. Satter sold 447,500 shares of the stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $0.36, for a total value of $161,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 11,833,277 shares of company stock worth $4,260,645. 33.90% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in Vital Therapies by 163.8% during the second quarter. Bank of New York Mellon Corp now owns 87,942 shares of the company’s stock worth $602,000 after buying an additional 54,611 shares during the period. Granahan Investment Management Inc. MA lifted its holdings in Vital Therapies by 9.3% during the second quarter. Granahan Investment Management Inc. MA now owns 607,696 shares of the company’s stock worth $4,163,000 after buying an additional 51,484 shares during the period. Redmile Group LLC purchased a new stake in Vital Therapies during the second quarter worth $7,502,000. BlackRock Inc. lifted its holdings in Vital Therapies by 134.8% during the second quarter. BlackRock Inc. now owns 2,242,025 shares of the company’s stock worth $15,356,000 after buying an additional 1,287,310 shares during the period. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Vital Therapies during the second quarter worth $388,000. 32.62% of the stock is currently owned by institutional investors.

About Vital Therapies (NASDAQ:VTL)

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Recommended Story: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.